Annarita Congedo
HIV’s drug formulations for long-term refillable subcutaneous drug release device.
Rel. Valentina Alice Cauda. Politecnico di Torino, Corso di laurea magistrale in Ingegneria Biomedica, 2025
Abstract
HIV (Human Immunodeficiency Virus) is a retrovirus that debilitates the immune system. In 2023, an estimated 39.9 million individuals live with HIV, with 1.3 million new infections and 630,000 AIDS-related passings. Without treatment, HIV advances to AIDS (Acquired Immunodeficiency Syndrome), severely impairing immunity. Early diagnosis and consistent treatment are pivotal. Antiretroviral therapy (ART) is the cornerstone of HIV treatment. ART reduces viral loads to undetectable levels, preventing progression and transmission. However, ART requires strict daily adherence to avoid drug resistance, presenting a major challenge for long-term treatment consistency. To overcome this, a subcutaneous implantable device (NanoDDI) enables continuous drug release for at least two years from a single hand injection.
It consists of a drug reservoir, a porous nanochannel membrane, a titanium filter, and two self-sealing silicon rubber ports
Relatori
Anno Accademico
Tipo di pubblicazione
Numero di pagine
Informazioni aggiuntive
Corso di laurea
Classe di laurea
Ente in cotutela
Aziende collaboratrici
URI
![]() |
Modifica (riservato agli operatori) |
